Kodiak Sciences Inc.
We are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. Our most advanced product candidate is KSI-301, a biologic therapy built with our antibody biopolymer conjugate platform, or ABC Platform, which is designed to maintain potent and effective drug levels in ocular tissues. We believe that KSI-301, if approved, has the potential to become an important anti-VEGF therapy in wet age-related macular degeneration, or wet AMD, and diabetic retinopathy, or DR. KSI-301 and our ABC Platform were developed at Kodiak, and we own worldwide rights to those assets, including composition of matter patent protection for KSI-301. We have applied our ABC Platform to develop additional product candidates beyond KSI-301, including KSI-501, our bispecific anti-IL-6/VEGF bioconjugate. We intend to progress these and other product candidates to address high-prevalence ophthalmic diseases.
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||2631 Hanover Street, Palo Alto, CA 94304, US|
|Phone Number||(650) 281-0850|
|View Prospectus:||Kodiak Sciences Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-32.48 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$90.0 mil|
|Manager / Joint Managers||Morgan Stanley/ BofA Merrill Lynch|
|Expected To Trade:||10/4/2018|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|